account_balance
Investment manager · 13F filer · SEC CIK 1687078
MPM Bioimpact LLC
Reported value$1.64Bas of Jun 30, 2026
Positions37 7 new, 11 sold out
Top 10 weight55.3%CGEM alone is 11%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
CGEMCullinan Therapeutics, Inc.
10.8%Added +27%
AKTSAktis Oncology, Inc.
9.5%
LQDALiquidia Corporation
6.7%
RVMDRevolution Medicines, Inc.
5.6%Trimmed −3%
CORTCorcept Therapeutics, Inc.
4.1%Trimmed −22%
EWTXEdgewise Therapeutics Inc
4.0%Trimmed −2%
TVTXTravere Therapeutics Inc
3.9%
DBVTDBV Technologies S A
3.7%Trimmed −30%
TRVITrevi Therapeutics Inc
3.5%Trimmed −7%
ALMSAlumis Inc
3.5%Trimmed −15%
QUREUniqure NV
3.4%Trimmed −10%
RAREUltragenyx Pharmaceuticals, Inc.
2.9%New
CGEMCullinan Therapeutics, Inc.
10.8%Added +27%
AKTSAktis Oncology, Inc.
9.5%
LQDA6.7%RVMD5.6%CORT4.1%EWTX4.0%TVTX3.9%DBVT3.7%TRVI3.5%ALMS3.5%QURE3.4%RARE2.9%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
CGEM Cullinan Therapeutics, Inc. 10.8% Added +27%AKTS Aktis Oncology, Inc. 9.5% HeldLQDA Liquidia Corporation 6.7% HeldRVMD Revolution Medicines, Inc. 5.6% Trimmed −3%CORT Corcept Therapeutics, Inc. 4.1% Trimmed −22%EWTX Edgewise Therapeutics Inc 4.0% Trimmed −2%TVTX Travere Therapeutics Inc 3.9% HeldDBVT DBV Technologies S A 3.7% Trimmed −30%TRVI Trevi Therapeutics Inc 3.5% Trimmed −7%ALMS Alumis Inc 3.5% Trimmed −15%QURE Uniqure NV 3.4% Trimmed −10%RARE Ultragenyx Pharmaceuticals, Inc. 2.9% New
What changed